Chloral hydrate - a sedative/ Hypnotic drug

Chloral hydrate is a CNS depressant drug that is used for the short term treatment of insomnia. It is not approved for use in the United States. It is used as a sedative drug prior to diagnostic tests and electroencephalogram, and as a sedative and hypnotic drug prior to surgical procedures. It is no longer recommended for pain control, alcohol, opioid, and barbiturate withdrawal, and for insomnia as previously recommended by the manufacturer.

Chloral hydrate Dose in Adults

Chloral hydrate for Procedural sedation:

  • 500 - 1,000 mg half-an-hour before the procedure

Chloral hydrate Dose in Children

Use for Sedation in mechanically-ventilated patients:

  • Infants, Children, and Adolescents:
    • 8 - 25 mg/kg/dose three or four times a day.
    • Titrate the dose up to 50 mg/kg/dose four times a day to a maximum of 1000 mg/dose.

Use for Sedation prior to a procedure (like echocardiogram or EEG):

  • Infants and Children
    • 25 - 100 mg/kg/dose half an hour before the procedure to a maximum dose of 1,000 mg/dose.
    • The dose may be repeated after 30 minutes to 25 - 50 mg/kg/dose.
    • The maximum total dose should not exceed 100 mg/kg/procedure or 2000 mg/procedure

Pregnancy Risk Factor C

  • It crosses the placental boundary.
  • The neonate may experience withdrawal symptoms if long-term medication is taken during pregnancy.

Use while breastfeeding

  • It can cause sedation in neonates and breastmilk. It should be avoided by lactating mothers.

Chloral hydrate Dose in Renal Disease:

Patients with mild to moderate renal impairment should use the drug with caution and those with severe kidney impairment(eGFR of less than 30 ml/min) should avoid its use. It is dialyzable.

Chloral hydrate Dose in Liver Disease:

Patients with mild to moderate hepatic impairment should use the drug with caution and those with severe hepatic impairment should avoid its use.

Common Side Effects Of Chloral hydrate include:

  • Cardiovascular:

    • Atrial arrhythmia
    • Depression of myocardial contractility
    • Hypotension
    • Shortening of refractory periods
    • Torsades de pointes
    • Ventricular arrhythmia
  • Central nervous system:

    • Abnormal gait
    • Ataxia
    • Confusion
    • Delirium
    • Dizziness
    • Drowsiness
    • Physical and psychological drug dependence with prolonged use or large doses.
    • Hallucinations
    • Hangover effect
    • Malaise
    • Nightmares
    • Paradoxical excitation
    • Somnambulism
    • Vertigo
  • Dermatologic:

    • Skin rash including urticaria, erythema, eczematoid dermatitis, scarlatiniform exanthems
  • Endocrine & metabolic:

    • Acute porphyria
    • Ketonuria
  • Gastrointestinal:

    • Diarrhea
    • Flatulence
    • Gastric irritation
    • Nausea
    • Vomiting
  • Hematologic & oncologic:

    • Acute porphyria
    • Eosinophilia
    • Leukopenia
  • Ophthalmic:

    • Allergic conjunctivitis
    • Blepharoptosis
    • Keratoconjunctivitis
  • Otic:

    • Increased middle ear pressure in infants and children.
  • Respiratory:

    • Airway obstruction may occur in young children.
    • Laryngeal edema
  • Miscellaneous:

    • Drug tolerance

Contraindication to Chloral hydrate include:

  • Allergy to the drug (chloralhydrate or any component)
  • Advanced liver disease
  • Renal impairments are common

Warnings and Precautions

  • Depression in the CNS:
    • Patients who use heavy machinery or perform skilled tasks that require mental alertness must be cautious and advised of its side effects.
  • Cardiac disease
    • Patients with heart disease may experience hypotension and arrhythmias, especially if they are given larger doses.
  • Gastrointestinal Disorders:
    • Because of its irritant properties, patients with gastritis or esophagitis should be cautious about using the drug.
  • Porphyria
    • It could cause porphyria.
  • Respiratory disease
    • Patients suffering from chronic neuromuscular or respiratory disease should be cautious about using the drug as it can cause respiratory failure.

Chloral hydrate (United States: Not available): Drug Interaction

Note: Drug Interaction Categories:

  • Risk Factor C: Monitor When Using Combination
  • Risk Factor D: Consider Treatment Modification
  • Risk Factor X: Avoid Concomitant Use

Risk Factor C (Monitor therapy).

Alcohol (Ethyl). CNS Depressants can increase the CNS depressant effects of Alcohol (Ethyl).
Alizapride CNS Depressants may increase the CNS depressant effects.
Brexanolone CNS Depressants can increase the CNS depressant effects of Brexanolone.
Brimonidine CNS Depressants may increase the CNS depressant effects.
Bromopride CNS Depressants may increase the CNS depressant effects.
Cannabidiol CNS Depressants may increase the CNS depressant effects.
Cannabis CNS Depressants may increase the CNS depressant effects.
Chlorphenesin Carbamate CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
CNS Depressants Can increase the toxic/adverse effects of CNS Depressants.
Dimethindene (Topical). CNS Depressants may increase the CNS depressant effects.
Doxylamine CNS Depressants may have a greater CNS depressant effect if taken with other CNS Depressants. Management: Diclegis (doxylamine/pyridoxine), which is intended for pregnancy, has specifically stated that it should not be used with any other CNS depressants.
Dronabinol CNS Depressants may increase the CNS depressant effects.
Esketamine CNS Depressants may increase the CNS depressant effects.
HydrOXYzine CNS Depressants may increase the CNS depressant effects.
Kava Kava CNS Depressants may have an adverse/toxic effect that can be exacerbated by them.
Lofexidine CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph.
Magnesium Sulfate CNS Depressants may increase the CNS depressant effects.
Melatonin May increase the sedative effects of Hypnotics, (Nonbenzodiazepine).
MetyroSINE MetyroSINE may have a sedative effect that can be enhanced by CNS depressants.
Minocycline CNS Depressants may increase the CNS depressant effects.
Mirtazapine CNS Depressants can increase the CNS depressant effects of Mirtazapine.
Nabilone CNS Depressants may increase the CNS depressant effects.
Piribedil CNS Depressants could increase the CNS depressant effects of Piribedil.
Pramipexole Pramipexole may have a greater sedative effect if it is combined with CNS depressants.
ROPINIRole CNS Depressants can increase the sedative effects of ROPINIRole.
Rotigotine CNS Depressants can increase the sedative effects of Rotigotine.
Rufinamide CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased.
Selective Serotonin Reuptake inhibitors CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased.
Tetrahydrocannabinol CNS Depressants may increase the CNS depressant effects.
Tetrahydrocannabinol, and Cannabidiol CNS Depressants may increase the CNS depressant effects.
Trimeprazine CNS Depressants may increase the CNS depressant effects.
Vitamin K antagonists (e.g. warfarin). The serum concentrations of Vitamin K Antagonists may be increased by chloral hydrate.

Risk Factor D (Be aware of therapy modification)

 
Blonanserin CNS Depressants can increase the CNS depressant effects of Blonanserin.
Buprenorphine CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Reduced doses of CNS depressants should be considered and avoidance of such drugs for patients at high risk of buprenorphine self-injection/overuse. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults when taken with other CNS depression drugs.
Chlormethiazole CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used.
Droperidol CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph.
Flunitrazepam CNS Depressants can increase the CNS depressant effects of Flunitrazepam.
HYDROcodone CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Methotrimeprazine Methotrimeprazine may have a higher CNS depressant activity than CNS Depressants. Methotrimeprazine can increase the CNS depressant effects of CNS Depressants. Management: Lower the adult dose of CNS Depressants by 50% and start concomitant methotrimeprazine treatment. After clinically proven efficacy of methotrimeprazine, further CNS depressant dose adjustments should only be made.
Opioid Agonists CNS Depressants can increase the CNS depressant effects of Opioid Aggonists. Management: When possible, avoid concomitant use opioid agonists and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
OxyCODONE CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Perampanel CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination.
Suvorexant CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia.
Tapentadol CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined.
Zolpidem CNS Depressants can increase the CNS depressant effects of Zolpidem. Management: For men who also take CNS depressants, reduce the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg. For women, no dose adjustment is advised. Avoid using CNS depressants at night; do not use alcohol.

Risk Factor X (Avoid Combination)

 
Azelastine - Nasal CNS Depressants could increase the CNS depressant effects of Azelastine.
Bromperidol CNS Depressants may increase the CNS depressant effects.
Furosemide Might increase the toxic/adverse effects of Chloral Hydrate.
Orphenadrine Orphenadrine may be more effective against CNS depression than other drugs.
Oxomemazine CNS Depressants may increase the CNS depressant effects.
Paraldehyde Paraldehyde may be enhanced by CNS Depressants.
Sodium Oxybate The CNS depressant effects of Sodium Oxybate may be enhanced by Hypnotics (Nonbenzodiazepine).
Thalidomide CNS Depressants can increase Thalidomide's CNS depressant effects.

 Monitoring Parameters:

When used for conscious sedation, Monitor:

  • Vital signs
  • Oxygen saturation

How to take Chloral hydrate?

  • It is administered orally.
  • The syrup may be diluted in water or other oral liquid to reduce dyspepsia and gastric irritation. 

Mechanism of action of Chloral hydrate:

  • Chloralhydrate is a sedative/hypnotic drug used to treat short-term insomnia. 
  • It is a central nervous system depressant because of its active metabolite, trichloroethanol.
  • It works wellIntakeThe onset of action takes between 15 and 30 minutes, with a duration of approximately 1 to 2 hours.

Active metabolites are competing with bilirubin to be albumin binding sites. It is growing rapidlyMetabolizedBy the enzyme alcohol deshydrogenase found in the liver to its activemetabolites trichloroethanol. It has been aEliminating half-lifePreterm infants are usually given approximately one hour, term neonates 3 - 6 hours, and children and teens 9 - 7 hours.

TheEliminating half-lifeThe active metabolite, tricholoroethanol, takes approximately 40+/- 14 hours in preterm babies, 27 +/ 21 hours for term infants, 9.6 +/-11.7 hours in children and adolescents, 8 - 12 hours for adults. It isExcretedThey are found primarily in the urine as metabolites.

International Brands of Chloral hydrate:

  • Chloral Hydrate Odan
  • PMS-Chloral Hydrate
  • Chloradorm
  • Chloraldurat
  • Chloralhydrat 500
  • Escre
  • Kloral
  • Pocral
  • Welldorm

Chloral hydrate brands in Pakistan:

Chloral Hydrate [Syrup 500 M/5ml]

Cedate Martin Dow Pharmaceuticals (Pak) Ltd.

 

Chloral Hydrate [Syrup 0.5 Mg/5ml]

Apnotek Euro Pharma International

 

Chloral Hydrate [Syrup 500 Mg/5ml]

Chloral Hydrate Specific Research Laboratories

 

Comments

NO Comments Found